Literature DB >> 2468710

Differences in surface phenotype between cytolytic and non-cytolytic CD4+ T cells. MHC class II-specific cytotoxic T lymphocytes lack Leu 8 antigen and express CD2 in high density.

S Takada1, J Koide, E G Engleman.   

Abstract

A number of cell surface molecules are differentially expressed on functionally distinct subsets of CD4+ T cells. However, to date CD4+ T cells capable of becoming CTL have not been shown to be phenotypically distinct from other CD4+ T cells, and in the current study we examined the ability of Leu 8+ and Leu 8- CD4+ subpopulations to become cytotoxic effectors after their stimulation with allogeneic lymphoblastoid cell lines. Although CD4+, Leu 8+ cells proliferated more vigorously than CD4+, Leu 8- cells in primary cultures stimulated with allogeneic LCL, the CD4+, Leu 8- population was the major source of cytotoxic effectors, killing targets with specificity for their class II MHC alloantigens. In most subjects, CD4+ precursors of CTL were distinguished not only by their lack of Leu 8 expression but also by their relatively high density of CD2, LFA-1, and LFA-3, molecules known to mediate non-specific cell-to-cell adhesion and postulated to be markers of immunologic memory. The absence of Leu 8 does not appear to be a reliable memory cell marker, however, because Leu 8+ as well as Leu 8-, CD4+ cells from PPD skin test positive subjects responded to the recall Ag, PPD. During 3 mo of continuous culture with allogeneic stimulators, Leu 8- cells retained their cytolytic activity and remained unreactive with anti-Leu 8 mAb, whereas Leu 8+ cells remained non-cytolytic and reactive with anti-Leu 8, suggesting that under the conditions used the Leu 8 phenotype is relatively stable. PHA or anti-CD3 mAb enhanced non-specific killing by alloantigen-stimulated CD4+,Leu 8- lines but failed to unmask any cytolytic potential in CD4+,Leu 8+ lines. We conclude that MHC class II-specific cytolytic CD4+ T cells can be distinguished from non-cytolytic CD4+ cells on the basis of their surface phenotype, and that most CD4+ CTL are contained within the Leu 8- subpopulation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2468710

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

Review 1.  Multiple roles of Leu-8/MEL-14 in leukocyte adhesion and function.

Authors:  S P James; Y Murakawa; M E Kanof; M Berg
Journal:  Immunol Res       Date:  1991       Impact factor: 2.829

2.  T cell interactions in active rheumatoid arthritis: insights from the human autologous mixed lymphocyte reaction as a model of T cell activation cascade.

Authors:  T Sakane; Y Murakawa; M Takeno; T Shigeki; H Nagafuchi; T Miki
Journal:  Clin Exp Immunol       Date:  1991-07       Impact factor: 4.330

3.  Lymphocyte activation and expression of the human leucocyte-endothelial cell adhesion molecule 1 (Leu-8/TQ1 antigen).

Authors:  C Bührer; C Berlin; H G Thiele; A Hamann
Journal:  Immunology       Date:  1990-11       Impact factor: 7.397

4.  Venular endothelium binding molecules CD44 and LECAM-1 in normal and malignant B-cell populations. A comparative study.

Authors:  P Möller; A Eichelmann; F Leithäuser; G Mechtersheimer; H F Otto
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

5.  L-selectin expression differentiates T cells isolated from different lymphoid tissues in cattle but does not correlate with memory.

Authors:  C J Howard; P Sopp; K R Parsons
Journal:  Immunology       Date:  1992-10       Impact factor: 7.397

6.  Heterogeneity in cytokine profiles of Babesia bovis-specific bovine CD4+ T cells clones activated in vitro.

Authors:  W C Brown; V M Woods; D A Dobbelaere; K S Logan
Journal:  Infect Immun       Date:  1993-08       Impact factor: 3.441

7.  In vivo and in vitro expression of adhesion molecules by peripheral blood lymphocytes from patients with primary Sjogren's syndrome: culture-associated enhancement of LECAM-1 and CD44.

Authors:  K E Aziz; D Wakefield
Journal:  Rheumatol Int       Date:  1995       Impact factor: 2.631

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.